https://archive.ph/8fBYY

SAN DIEGO—RNA vaccines packaged in tiny fatty containers called nanoparticles saved tens of millions from COVID-19. Now, researchers are trying to use similar nanoparticles to fight two other major killers, respiratory failure caused by lung infections such as flu and the atherosclerosis that leads to heart attacks and strokes. In both conditions, the endothelial cells that line blood vessels malfunction, turning down key genes. New research presented at the American Chemical Society (ACS) meeting here this week shows that nanoparticles carrying a payload of RNA can ramp the genes back up, promising to address the diseases at their root.

Nanoparticles are a familiar tool in medicine, but the scheme to use them to treat endothelial cells is “excellent work,” says Robert Langer, a nanoparticle therapy pioneer at the Massachusetts Institute of Technology. Won Hyuk Suh, a biomaterials expert at the University of New Hampshire who organized the scientific session at the ACS meeting, notes that the findings are preliminary but calls them “very interesting and promising.” They were posted on the bioRxiv preprint server in January.